These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38865742)

  • 1. Small molecule inhibitors targeting heat shock protein 90: An updated review.
    Li Y; Dong J; Qin JJ
    Eur J Med Chem; 2024 Sep; 275():116562. PubMed ID: 38865742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions.
    Hong DS; Banerji U; Tavana B; George GC; Aaron J; Kurzrock R
    Cancer Treat Rev; 2013 Jun; 39(4):375-87. PubMed ID: 23199899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and biological evaluation of a series of resorcinol-based N-benzyl benzamide derivatives as potent Hsp90 inhibitors.
    Park SY; Oh YJ; Lho Y; Jeong JH; Liu KH; Song J; Kim SH; Ha E; Seo YH
    Eur J Med Chem; 2018 Jan; 143():390-401. PubMed ID: 29202402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
    Kim T; Keum G; Pae AN
    Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.
    Donnelly A; Blagg BS
    Curr Med Chem; 2008; 15(26):2702-17. PubMed ID: 18991631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based virtual screening and optimization of modulators targeting Hsp90-Cdc37 interaction.
    Wang L; Li L; Zhou ZH; Jiang ZY; You QD; Xu XL
    Eur J Med Chem; 2017 Aug; 136():63-73. PubMed ID: 28482218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.
    Garg G; Khandelwal A; Blagg BS
    Adv Cancer Res; 2016; 129():51-88. PubMed ID: 26916001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of N-pyridoyl-Δ
    Kadasi S; Yerroju R; Gaddam S; Pullanagiri N; Chary M; Pingili D; Raj S; Raghavendra NM
    Arch Pharm (Weinheim); 2020 Feb; 353(2):e1900192. PubMed ID: 31808979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting heat-shock-protein 90 (Hsp90) by natural products: geldanamycin, a show case in cancer therapy.
    Franke J; Eichner S; Zeilinger C; Kirschning A
    Nat Prod Rep; 2013 Oct; 30(10):1299-323. PubMed ID: 23934201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using natural product inhibitors to validate Hsp90 as a molecular target in cancer.
    Neckers L
    Curr Top Med Chem; 2006; 6(11):1163-71. PubMed ID: 16842153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Divergent synthesis of a pochonin library targeting HSP90 and in vivo efficacy of an identified inhibitor.
    Barluenga S; Wang C; Fontaine JG; Aouadi K; Beebe K; Tsutsumi S; Neckers L; Winssinger N
    Angew Chem Int Ed Engl; 2008; 47(23):4432-5. PubMed ID: 18435518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
    Stravopodis DJ; Margaritis LH; Voutsinas GE
    Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and development of pyrazole-scaffold Hsp90 inhibitors.
    McDonald E; Jones K; Brough PA; Drysdale MJ; Workman P
    Curr Top Med Chem; 2006; 6(11):1193-203. PubMed ID: 16842156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An updated patent review of anticancer Hsp90 inhibitors (2013-present).
    Li L; Chen NN; You QD; Xu XL
    Expert Opin Ther Pat; 2021 Jan; 31(1):67-80. PubMed ID: 32990109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural heat shock protein 90 inhibitors in cancer and inflammation.
    Costa TEMM; Raghavendra NM; Penido C
    Eur J Med Chem; 2020 Mar; 189():112063. PubMed ID: 31972392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Limonol Derivatives as Heat Shock Protein 90 (Hsp90) Inhibitors through a Multidisciplinary Approach.
    Chini MG; Malafronte N; Vaccaro MC; Gualtieri MJ; Vassallo A; Vasaturo M; Castellano S; Milite C; Leone A; Bifulco G; De Tommasi N; Dal Piaz F
    Chemistry; 2016 Sep; 22(37):13236-50. PubMed ID: 27492719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and biological evaluation of biphenylamide derivatives as Hsp90 C-terminal inhibitors.
    Zhao H; Garg G; Zhao J; Moroni E; Girgis A; Franco LS; Singh S; Colombo G; Blagg BS
    Eur J Med Chem; 2015 Jan; 89():442-66. PubMed ID: 25462258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hsp90 inhibitors and drugs from fragment and virtual screening.
    Roughley S; Wright L; Brough P; Massey A; Hubbard RE
    Top Curr Chem; 2012; 317():61-82. PubMed ID: 21647838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Signal Transducer and Activator of Transcription Protein 3 (STAT3): An Update on its Direct Inhibitors as Promising Anticancer Agents.
    Gelain A; Mori M; Meneghetti F; Villa S
    Curr Med Chem; 2019; 26(27):5165-5206. PubMed ID: 30027840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of hsp90 inhibitors as anti-cancer drugs.
    Xiao L; Lu X; Ruden DM
    Mini Rev Med Chem; 2006 Oct; 6(10):1137-43. PubMed ID: 17073714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.